Solid Biosciences Inc. (SLDB): Price and Financial Metrics

Solid Biosciences Inc. (SLDB): $9.82

0.18 (-1.80%)

POWR Rating

Component Grades

Momentum

C

Stability

D

Sentiment

Quality

C

Add SLDB to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#138 of 363

in industry

SLDB Price/Volume Stats

Current price $9.82 52-week high $15.05
Prev. close $10.00 52-week low $1.81
Day low $9.75 Volume 130,758
Day high $10.06 Avg. volume 335,855
50-day MA $10.78 Dividend yield N/A
200-day MA $5.79 Market Cap 370.77M

SLDB Stock Price Chart Interactive Chart >


Solid Biosciences Inc. (SLDB) Company Bio


Solid Biosciences, LLC engages in identifying and developing gene therapies for duchenne muscular dystrophy in the United States. Its lead product candidate includes SGT-001, a gene transfer candidate that is in Phase I/II clinical trial to restore functional dystrophin protein expression in patients’ muscles. The company was formerly known as Solid Ventures, LLC and changed its name to Solid Biosciences, LLC in June 2015. Solid Biosciences, LLC was founded in 2013 and is based in Cambridge, Massachusetts.


SLDB Latest News Stream


Event/Time News Detail
Loading, please wait...

SLDB Latest Social Stream


Loading social stream, please wait...

View Full SLDB Social Stream

Latest SLDB News From Around the Web

Below are the latest news stories about SOLID BIOSCIENCES INC that investors may wish to consider to help them evaluate SLDB as an investment opportunity.

While institutions invested in Solid Biosciences Inc. (NASDAQ:SLDB) benefited from last week's 68% gain, private equity firms stood to gain the most

Key Insights The considerable ownership by private equity firms in Solid Biosciences indicates that they collectively...

Yahoo | December 9, 2023

Solid Biosciences' (SLDB) DMD Drug Gets Fast Track Tag, Stock Up

Solid Biosciences (SLDB) gains 68% as the FDA grants Fast Track designation to the company's gene therapy candidate, SGT-003, for the treatment of Duchenne muscular dystrophy.

Yahoo | December 8, 2023

Solid Biosciences Receives FDA Fast Track Designation for Duchenne Muscular Dystrophy Gene Therapy SGT-003

– Next-generation gene transfer therapy to treat Duchenne receives FDA Fast Track Designation – CHARLESTOWN, Mass., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that it has received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for SGT-003, the company’s next-generation Duchenne muscular dystrophy (Duchenne) gene therapy cand

Yahoo | December 7, 2023

Solid Biosciences to Participate at 35th Annual Piper Sandler Healthcare Conference

CHARLESTOWN, Mass., Nov. 22, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Cumbo, President and Chief Executive Officer, will present at the Piper Sandler Healthcare Conference on Thursday, November 30, 2023, at 1:00 pm ET. A live webcast of the presentation will be available on the Events page of the Investors section of the Company website or by click

Yahoo | November 22, 2023

The Zacks Analyst Blog Highlights Arcellx, Bristol Myers Squibb, Solid Biosciences, Vertex Pharmaceuticals and CRISPR Therapeutics

Arcellx, Bristol Myers Squibb, Solid Biosciences, Vertex Pharmaceuticals and CRISPR Therapeutics are included in this Analyst Blog.

Yahoo | November 17, 2023

Read More 'SLDB' Stories Here

SLDB Price Returns

1-mo -24.92%
3-mo 21.84%
6-mo 356.74%
1-year 94.84%
3-year -87.01%
5-year -92.89%
YTD 59.93%
2023 14.13%
2022 -79.50%
2021 -76.91%
2020 70.34%
2019 -83.40%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!